Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 4/2009

01-09-2009 | Original Article

Phase II trial of S-1 in combination with gemcitabine for chemo-naïve patients with locally advanced or metastatic pancreatic cancer

Authors: Gyeong-Won Lee, Hye Jung Kim, Ji-Hyun Ju, Seok-Hyun Kim, Hoon Gu Kim, Tae Hyo Kim, Hyun Jin Kim, Chi-Young Jeong, Jung Hun Kang

Published in: Cancer Chemotherapy and Pharmacology | Issue 4/2009

Login to get access

Abstract

Background

We performed a phase II study of combination chemotherapy with S-1 plus gemcitabine for treating chemo-naïve patients with unresectable pancreatic cancer to evaluate the efficacy and toxicity.

Patients and methods

Patients with histologically confirmed unresectable pancreatic cancer were eligible. The treatment consisted of S-1 (40 mg/m2 p.o. b.i.d. from D1 to 14) and gemcitabine (1,250 mg/m2 on D1 and 8), repeated every 3 weeks.

Results

Thirty-two patients were enrolled between March 2005 and December 2007. No complete response was observed and a partial response was observed in 14 patients (44.0%), stable disease in eight patients (25.0%), and progressive disease in eight patients (25.0%). The median time to progression was 4.92 months (95% CI: 4.16–5.67 months), and the median overall survival was 7.89 months (95% CI: 5.96–9.82 months). The survival duration was significantly longer for the patients with a good performance status compared with that of the patients with a poor performance status. The major toxicities were grade 3–4 neutropenia (9, 28.1%), grade 3/4 thrombocytopenia (5, 15.6%), and grade 3 diarrhea (5, 15.6%).

Conclusion

The combination chemotherapy of S-1 and gemcitabine showed promising antitumor activity and manageable toxicities, and especially for the good performance status patients with unresectable pancreatic cancer.
Literature
1.
Sultana A, Smith CT, Cunningham D et al (2007) Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol 25(18):2607–2615PubMedCrossRef
2.
Cullinan S, Moertel CG, Wieand HS et al (1990) A phase III trial on the therapy of advanced pancreatic carcinoma. Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin. Cancer 65(10):2207–2212PubMedCrossRef
3.
Kim NK, Park YS, Heo DS et al (1993) A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 71(12):3813–3818PubMedCrossRef
4.
Ducreux M, Rougier P, Pignon JP et al (2002) A randomized trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma. Ann Oncol 13(8):1185–1191PubMedCrossRef
5.
Ducreux M, Mitry E, Ould-Kaci M et al (2004) Randomized phase II study evaluating oxaliplatin alone, oxaliplatin combined with infusional 5-FU, and infusional 5-FU alone in advanced pancreatic carcinoma patients. Ann Oncol 15(3):467–473PubMedCrossRef
6.
Earle CC, Agboola O, Maroun J et al (2003) The treatment of locally advanced pancreatic cancer: a practice guideline. Can J Gastroenterol 17(3):161–167PubMed
7.
Burris HA 3rd, Moore MJ, Andersen J et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15(6):2403–2413PubMed
8.
Fukushima M, Satake H, Uchida J et al (1999) Preclinical antitumor efficacy of S-1: a new oral formulation of 5-fluorouracil on human tumor xenografts. Int J Oncol 13(4):693–698
9.
Hirata K, Horikoshi N, Aiba K et al (1999) Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug. Clin Cancer Res 5(8):2000–2005PubMed
10.
van Groeningen CJ, Peters GJ, Schornagel JH et al (2000) Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors. J Clin Oncol 18(14):2772–2779PubMed
11.
Schöffski P (2004) The modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumors. Anticancer Drugs 15(2):85–106PubMedCrossRef
12.
Shirasaka T, Shimamoto Y, Fukushima M (1993) Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res 53:4004–4009PubMed
13.
Shirasaka T, Shimamato Y, Oshimo H et al (1996) Development of a novel form of oral 5-fluorouracil derivative directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7(5):548–557PubMedCrossRef
14.
Takechi T, Nakano K, Uchida J et al (1997) Antitumor activity and low intestinal toxicity of S-1, a new formulation of oral tegafur, in experimental tumor models in rats. Cancer Chemother Pharmacol 39(3):205–211PubMedCrossRef
15.
Nakahira S, Nakamori S, Tsujie M et al (2008) Pretreatment with S-1, an oral derivative of 5-fluorouracil, enhances gemcitabine effects in pancreatic cancer xenografts. Anticancer Res 28(1A):179–186PubMed
16.
Halloran CM, Ghaneh P, Shore S et al (2004) 5-Fluorouracil or gemcitabine combined with adenoviral-mediated reintroduction of p16INK4A greatly enhanced cytotoxicity in Panc-1 pancreatic adenocarcinoma cells. J Gene Med 6(5):514–525PubMedCrossRef
17.
Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors (RECIST) guidelines. J Natl Cancer Inst 92(3):205–216PubMedCrossRef
18.
Nakamura K, Yamaguchi T, Ishihara T et al (2006) Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer. Br J Cancer 94(11):1575–1579PubMed
19.
Murakami Y, Uemura K, Sudo T et al (2008) Adjuvant gemcitabine plus S-1 chemotherapy after surgical resection for pancreatic adenocarcinoma. Am J Surg. 195(6):757–762PubMedCrossRef
20.
Kaira K, Sunaga N, Yanagitani N et al (2008) Phase I trial of oral S-1 plus gemcitabine in elderly patients with nonsmall cell lung cancer. Anticancer Drugs 19(3):289–294PubMedCrossRef
21.
Zang DY, Yang DH, Lee HW et al (2008) Phase I/II trial with docetaxel and S-1 for patients with advanced or recurrent gastric cancer with consideration to age. Cancer Chemother Pharmacol. doi:10.​1007/​s00280-008-0768-9
22.
Heinemann V, Xu YZ, Chubb S et al (1990) Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′2′-difluorodeoxycytidine. Mol Pharmacol 38(4):567–572PubMed
23.
Mohammad RM, Dugan MC, Mohamed AN et al (1998) Establishment of a human pancreatic tumor xenograft model: potential application for preclinical evaluation of novel therapeutic agents. Pancreas 16(1):19–25PubMedCrossRef
24.
Park BB, Park JO, Lee HR et al (2007) A phase II trial of gemcitabine plus capecitabine for patients with advanced pancreatic adenocarcinoma. Cancer Chemother Pharmacol 60(4):489–494PubMedCrossRef
25.
Stathopoulos GP, Syrigos K, Polyzos A et al (2004) Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: an intergroup multicenter phase II study. Ann Oncol 15(2):224–229PubMedCrossRef
26.
Ishii H, Okada S, Nose H et al (1996) Prognostic factors in patients with advanced pancreatic cancer treated with systemic chemotherapy. Pancreas 12(3):267–271PubMedCrossRef
27.
Cubiella J, Castells A, Fondevila C et al (1999) Prognostic factors in nonresectable pancreatic adenocarcinoma: a rationale to design therapeutic trials. Am J Gastroenterol 94(5):1271–1278PubMedCrossRef
28.
Ueono H, Okada S, Okusaka T et al (2000) Prognostic factors in patients with metastatic pancreatic adenocarcinoma receiving systemic chemotherapy. Oncology 59(4):296–301CrossRef
29.
Marechal R, Demols A, Gay F et al (2007) Prognostic factors and prognostic index for chemonaive and gemcitabine-refractory patients with advanced pancreatic caner. Oncology 73(1–2):41–51PubMed
30.
Nakachi K, Furuse J, Ishii H et al (2007) Prognostic factors in patients with gemcitabine-refractory pancreatic cancer. Jpn J Clin Oncol 37(2):114–200PubMedCrossRef
31.
32.
Rich TA, Shepard RC, Mosley ST (2004) Four decades of continuing innovation with fluorouracil: current and future approaches to fluorouracil chemoradiation therapy. J Clin Oncol 22(11):2214–2232PubMedCrossRef
33.
Metadata
Title
Phase II trial of S-1 in combination with gemcitabine for chemo-naïve patients with locally advanced or metastatic pancreatic cancer
Authors
Gyeong-Won Lee
Hye Jung Kim
Ji-Hyun Ju
Seok-Hyun Kim
Hoon Gu Kim
Tae Hyo Kim
Hyun Jin Kim
Chi-Young Jeong
Jung Hun Kang
Publication date
01-09-2009
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue 4/2009
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-008-0918-0

Other articles of this Issue 4/2009

Cancer Chemotherapy and Pharmacology 4/2009 Go to the issue

Original Article

Single- and multiple-dose disposition kinetics of sunitinib malate, a multitargeted receptor tyrosine kinase inhibitor: comparative plasma kinetics in non-clinical species

Original Article

Pro-apoptotic and cytostatic activity of naturally occurring cardenolides

Original Article

Protection of mouse bone marrow from etoposide-induced genomic damage by dexrazoxane

Mini Review

Temozolomide in malignant gliomas: current use and future targets

Original Article

Carbonate and carbamate derivatives of 4-demethylpenclomedine as novel anticancer agents

Original Article

Indomethacin overcomes doxorubicin resistance by decreasing intracellular content of glutathione and its conjugates with decreasing expression of γ-glutamylcysteine synthetase via promoter activity in doxorubicin-resistant leukemia cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits